ME Therapeutics Added to CSE25 Index

Article content material

VANCOUVER, British Columbia — ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Firm”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology firm discovering and creating novel most cancers combating medication within the subject of immuno-oncology, introduced right now it has been added to the CSE25 Index, a signature benchmark of the Canadian Securities Trade.

Create an account or register to proceed along with your studying expertise.

Entry articles from throughout Canada with one account.
Share your ideas and be a part of the dialog within the feedback.
Take pleasure in extra articles per 30 days.
Get electronic mail updates out of your favorite authors.

Signal In or Create an Account

Article content material

The CSE25 Index consists of the twenty-five largest firms by market capitalization listed on the CSE. This sub-index holds over 75% of the whole market capitalization of the Composite Index, which is a gauge of the general efficiency of firms listed on the CSE.

Article content material

“We’re honoured that ME Therapeutics has made the CSE25 Index,” mentioned Salim Dhanji, CEO of ME Therapeutics. “We’re happy with the laborious work our crew is doing to advance our pipeline of immuno-oncology therapies that reprogram the tumour microenvironment. We’re grateful to our traders for his or her assist and recognition of our give attention to overcoming the suppressive results of immune cells to deliver novel therapies to most cancers sufferers.”

Article content material

About ME Therapeutics

Article content material

Myeloid Enhancement (ME) Therapeutics is a publicly listed biotechnology firm primarily based in Vancouver discovering and creating novel immuno-oncology therapeutics that reprogram the tumour microenvironment to battle most cancers. Our pipeline is aimed toward

Article content material

enhancing immune recognition of most cancers cells and overcoming immune suppression within the tumour microenvironment

Article content material

For extra info, go to

Article content material

Neither the Canadian Securities Trade nor any Market Regulator (as that time period is outlined within the insurance policies of the Canadian Securities Trade) accepts accountability for the adequacy or accuracy of this launch.

Article content material

Cautionary Assertion Concerning Ahead-Trying Statements

Article content material

This information launch contains sure “forward-looking statements” relating to ME Therapeutics’ enterprise and product candidates underneath relevant Canadian securities laws. Such statements will not be purely historic and embrace statements relating to licenses, partnerships, collaborations, analysis plans, examine timelines and outcomes, meant advantages of know-how, and enterprise improvement plans. Ahead-looking statements are topic to dangers and uncertainties which will trigger precise outcomes to vary materially, together with dangers associated to: the completion of the licensing transaction being delayed, not occurring as anticipated, or not being accomplished in any respect; analysis outcomes; regulatory approvals; mRNA and nanobody know-how improvement; reliance on third-party collaborators; delays in timelines; mental property safety; and funding availability. No assurance could be on condition that the occasions anticipated will happen or yield anticipated advantages. The Firm disclaims any obligation to replace forward-looking statements besides as required by legislation.

Article content material